4scar-276
Preclinical
4scar-276 is one of 40 therapeutic programs targeting Solid Tumor. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
348 competitors in Solid Tumor
#DrugCompanyPhaseTrials
1Fludara
SanofiPreclinical
DATROWAY
Daiichi SankyoPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Navmi
SSummit Therapeutics
Preclinical
Paxil
SSebela Pharmaceuticals Development LLC
Preclinical
Ifinatamab Deruxtecan
Daiichi SankyoPreclinical
Tulmimetostat
NovartisPreclinical
Carboplatin AUC-5
Merck & Co.Preclinical
MHB036C
MMinghui Pharmaceutical (Hangzhou) Ltd
Preclinical
IN10018
IInxMed (Shanghai) Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4scar-276. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]